Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 43

1.

Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia.

Oldach D, Clark K, Schranz J, Das A, Craft JC, Scott D, Jamieson BD, Fernandes P.

Antimicrob Agents Chemother. 2013 Jun;57(6):2526-34. doi: 10.1128/AAC.00197-13. Epub 2013 Mar 18.

2.

Review of pyronaridine anti-malarial properties and product characteristics.

Croft SL, Duparc S, Arbe-Barnes SJ, Craft JC, Shin CS, Fleckenstein L, Borghini-Fuhrer I, Rim HJ.

Malar J. 2012 Aug 9;11:270. doi: 10.1186/1475-2875-11-270.

3.

First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials.

Moehrle JJ, Duparc S, Siethoff C, van Giersbergen PL, Craft JC, Arbe-Barnes S, Charman SA, Gutierrez M, Wittlin S, Vennerstrom JL.

Br J Clin Pharmacol. 2013 Feb;75(2):524-37. doi: 10.1111/j.1365-2125.2012.04368.x.

4.

In vitro and in vivo activity of solithromycin (CEM-101) against Plasmodium species.

Wittlin S, Ekland E, Craft JC, Lotharius J, Bathurst I, Fidock DA, Fernandes P.

Antimicrob Agents Chemother. 2012 Feb;56(2):703-7. doi: 10.1128/AAC.05039-11. Epub 2011 Nov 14.

5.

A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections.

Craft JC, Moriarty SR, Clark K, Scott D, Degenhardt TP, Still JG, Corey GR, Das A, Fernandes P.

Clin Infect Dis. 2011 Jun;52 Suppl 7:S520-6. doi: 10.1093/cid/cir167.

PMID:
21546629
6.

Ensuring global access to quality medicines: role of the US Pharmacopeia.

USP council of convention section on global public health; USP council of experts international health expert committee; USP regionalization team, Heyman ML, Williams RL.

J Pharm Sci. 2011 Apr;100(4):1280-7. doi: 10.1002/jps.22391. Epub 2010 Nov 24. Review.

PMID:
24081465
7.

Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria.

Charman SA, Arbe-Barnes S, Bathurst IC, Brun R, Campbell M, Charman WN, Chiu FC, Chollet J, Craft JC, Creek DJ, Dong Y, Matile H, Maurer M, Morizzi J, Nguyen T, Papastogiannidis P, Scheurer C, Shackleford DM, Sriraghavan K, Stingelin L, Tang Y, Urwyler H, Wang X, White KL, Wittlin S, Zhou L, Vennerstrom JL.

Proc Natl Acad Sci U S A. 2011 Mar 15;108(11):4400-5. doi: 10.1073/pnas.1015762108. Epub 2011 Feb 7.

8.

Comparative embryotoxicity of different antimalarial peroxides: in vitro study using the rat whole embryo culture model (WEC).

Longo M, Zanoncelli S, Brughera M, Colombo P, Wittlin S, Vennerstrom JL, Moehrle J, Craft JC.

Reprod Toxicol. 2010 Dec;30(4):583-90. doi: 10.1016/j.reprotox.2010.07.011. Epub 2010 Aug 11.

PMID:
20708075
9.

Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial.

Tshefu AK, Gaye O, Kayentao K, Thompson R, Bhatt KM, Sesay SS, Bustos DG, Tjitra E, Bedu-Addo G, Borghini-Fuhrer I, Duparc S, Shin CS, Fleckenstein L; Pyronaridine-artesunate Study Team.

Lancet. 2010 Apr 24;375(9724):1457-67. doi: 10.1016/S0140-6736(10)60322-4.

PMID:
20417857
10.

Population pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjects.

Tan B, Naik H, Jang IJ, Yu KS, Kirsch LE, Shin CS, Craft JC, Fleckenstein L.

Malar J. 2009 Dec 18;8:304. doi: 10.1186/1475-2875-8-304.

11.

Challenges facing drug development for malaria.

Craft JC.

Curr Opin Microbiol. 2008 Oct;11(5):428-33. doi: 10.1016/j.mib.2008.09.003. Epub 2008 Oct 14. Review.

PMID:
18824124
12.

Medicines for Malaria Venture new developments in antimalarials.

Nwaka S, Riopel L, Ubben D, Craft JC.

Travel Med Infect Dis. 2004 Aug-Nov;2(3-4):161-70.

PMID:
17291977
13.
14.

ABT-773 overview.

Craft JC.

Jpn J Antibiot. 2001 Feb;54 Suppl A:62-3. Review. No abstract available.

PMID:
11296410
15.

Ketolide ABT-773 is active against Toxoplasma gondii.

Khan AA, Araujo FG, Craft JC, Remington JS.

J Antimicrob Chemother. 2000 Sep;46(3):489-92.

PMID:
10980181
16.

Dialectical behavior therapy for patients with borderline personality disorder and drug-dependence.

Linehan MM, Schmidt H 3rd, Dimeff LA, Craft JC, Kanter J, Comtois KA.

Am J Addict. 1999 Fall;8(4):279-92.

PMID:
10598211
17.
18.

Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration.

Carr RA, Edmonds A, Shi H, Locke CS, Gustavson LE, Craft JC, Harris SI, Palmer R.

Antimicrob Agents Chemother. 1998 May;42(5):1176-80.

19.

Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection.

Chaisson RE, Keiser P, Pierce M, Fessel WJ, Ruskin J, Lahart C, Benson CA, Meek K, Siepman N, Craft JC.

AIDS. 1997 Mar;11(3):311-7.

PMID:
9147422
20.

Ancillary benefits of Mycobacterium avium-intracellulare complex prophylaxis with clarithromycin in HIV-infected patients.

Jablonowski H, Fätkenheuer G, Youle M, Newell T, Lines S, Craft JC.

Drugs. 1997;54 Suppl 2:16-22; discussion 28-9.

PMID:
9358196

Supplemental Content

Loading ...
Support Center